ArticleBMC infectious diseases2025
Drug resistance mutations and phylogenetic analysis of HIV-1 subtypes B and F from mothers and children with vertical transmission.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to describe the transmission of drug-resistant HIV-1 variants and phylogenetic characterisation of viral strains in mother-child pairs from the cities of Recife and São Luís, located in the Northeast region of Brazil, in 2007-2022.
methodsThis study included 15 mother-child pairs with confirmed vertical transmission of HIV-1. The genotyping sequences were provided by the Brazilian Ministry of Health. The analyses included descriptions of antiretroviral resistance mutation profiles of the mothers and children, subtype determination, and phylogenetic analyses.
resultsSeven mother-child pairs exhibited similar mutation profiles, with three showing no mutations and four displaying similar resistance mutations to the nucleoside reverse transcriptase inhibitor (NRTI) and non-nucleoside reverse transcriptase inhibitor (NNRTI) drug classes. Among four pairs, mutation similarities were observed for only one antiretroviral drug class. In the remaining four pairs, distinct mutation profiles were noted, with two children having mutations in two or three drug classes and their mothers exhibiting no or one mutation. Among the eight pairs with tests obtained within the first four years after birth, six of them had very similar mutation profiles. Among the seven pairs with exams obtained five years or more after birth, four pairs presented very different DRAM profiles. Mutations conferring resistance to efavirenz, nevirapine, lamivudine, abacavir, and didanosine were frequently observed in children and mothers. Thirteen pairs (86.6%) were identified as having HIV-1 subtype B, while two (13.3%) were identified as having HIV-1 subtype F1.
conclusionsDifferences in mutation profiles and antiretroviral resistance for NRTI and NNRTI drug classes were observed in half of the mother-child pairs, emphasising the importance of individualised therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.